| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1092711796 |
| P356 | DOI | 10.1007/S00345-017-2115-4 |
| P932 | PMC publication ID | 5799348 |
| P698 | PubMed publication ID | 29147759 |
| P50 | author | Shahrokh Shariat | Q7462263 |
| Andrea Mari | Q51049589 | ||
| Mohammad Abufaraj | Q39051577 | ||
| Francesco Montorsi | Q67191520 | ||
| Riccardo Tellini | Q92808667 | ||
| P2093 | author name string | Andrea Minervini | |
| Giorgio Gandaglia | |||
| Marco Carini | |||
| Roland van Velthoven | |||
| Simone Albisinni | |||
| Georgios Hatzichristodoulou | |||
| Riccardo Campi | |||
| P2860 | cites work | Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. | Q50526344 |
| Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. | Q51687818 | ||
| Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. | Q51732754 | ||
| Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. | Q51839920 | ||
| The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. | Q52946591 | ||
| Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. | Q53035018 | ||
| Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. | Q53062494 | ||
| Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. | Q53085995 | ||
| The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. | Q53574858 | ||
| Evaluating non-randomised intervention studies | Q29619272 | ||
| Refining patient selection for neoadjuvant chemotherapy before radical cystectomy | Q30408866 | ||
| A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy | Q30981992 | ||
| Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. | Q33669763 | ||
| Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer | Q34226107 | ||
| Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis | Q34226276 | ||
| International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial | Q35023400 | ||
| Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling | Q36419132 | ||
| Does patient age affect survival after radical cystectomy? | Q38007021 | ||
| Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy | Q38090151 | ||
| Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. | Q38163229 | ||
| Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. | Q38594015 | ||
| Preoperative Anemia and Low Hemoglobin Level Are Associated With Worse Clinical Outcomes in Patients With Bladder Cancer Undergoing Radical Cystectomy: A Meta-Analysis | Q38963720 | ||
| Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. | Q39010863 | ||
| Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients | Q39046515 | ||
| Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades | Q39397592 | ||
| The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy | Q39657030 | ||
| Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. | Q40668752 | ||
| Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. | Q40714046 | ||
| Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy | Q41085821 | ||
| Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy | Q41647263 | ||
| Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? | Q41737126 | ||
| Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy | Q43622475 | ||
| Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy | Q43742712 | ||
| Development and external validation of lymph node density cut-off points in prospective series of radical cystectomy and pelvic lymph node dissection | Q44042378 | ||
| Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study | Q44276267 | ||
| Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy | Q44519064 | ||
| Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study | Q44818814 | ||
| Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study | Q45325031 | ||
| Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis | Q45363607 | ||
| Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. | Q45905367 | ||
| The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. | Q45935262 | ||
| Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. | Q46384526 | ||
| Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy | Q46776204 | ||
| Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer | Q57238997 | ||
| Gender differences in stage distribution of bladder cancer | Q57307308 | ||
| Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men? | Q57586314 | ||
| Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy | Q79163021 | ||
| Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy | Q79369638 | ||
| Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report | Q79907956 | ||
| Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer | Q79976034 | ||
| Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy | Q80274704 | ||
| The effects of stage divergence on survival after radical cystectomy for urothelial cancer | Q81712644 | ||
| Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy | Q84184617 | ||
| Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery | Q84323387 | ||
| Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy | Q85598854 | ||
| Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study | Q85918736 | ||
| Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer | Q86698424 | ||
| Smoking and survival after radical cystectomy for bladder cancer | Q87417530 | ||
| The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder | Q87621622 | ||
| Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma | Q95407126 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystectomy | Q245995 |
| lymphadenectomy | Q1809305 | ||
| transitional cell carcinoma | Q2501186 | ||
| local neoplasm recurrence | Q54945651 | ||
| bladder neoplasm | Q55949884 | ||
| Radical cystectomy | Q111329312 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 157-170 | |
| P577 | publication date | 2017-11-16 | |
| 2018-02-01 | |||
| P1433 | published in | World Journal of Urology | Q15750774 |
| P1476 | title | Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature | |
| P478 | volume | 36 |
| Q92382708 | A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer |
| Q64977058 | A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors. |
| Q90615453 | Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma |
| Q99578183 | Can anesthetics affect bladder cancer recurrence? Total intravenous versus volatile anesthesia in patients undergoing robot-assisted radical cystectomy: A single institution retrospective analysis |
| Q64236929 | Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling |
| Q57192145 | Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer |
| Q95584529 | EDITORIAL COMMENT |
| Q102060646 | Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder |
| Q89485731 | Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions |
Search more.